There was an error in the Competing Interests statement. The authors would like to apologize for this omission and would like to disclose the following information: Dr. Tanzi serves as a consultant to, and is shareholder in Prana Biotechnology, LTD, which is developing the Alzheimer's therapeutic compound, PBT2.
Citation: Craddock TJA, Tuszynski JA, Chopra D, Casey N, Goldstein LE, Hameroff SR, et al. (2012) Correction: The Zinc Dyshomeostasis Hypothesis of Alzheimer's Disease. PLoS ONE 7(4): 10.1371/annotation/57c710a6-83ba-444c-a352-b9f60125f2fa. https://doi.org/10.1371/annotation/57c710a6-83ba-444c-a352-b9f60125f2fa
Published: April 03, 2012
Copyright: © 2012 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing interests: No competing interests declared.